Cardiac Slc25a49 ‐Mediated Energy Reprogramming Governs Doxorubicin‐Induced Cardiomyopathy through the G6P–AP‐1–Sln Axis
Advanced Science · 2025
DOI: 10.1002/advs.202502163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Sitong Wan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing, 100193, China. Hauptthemen laut MEDLINE: Doxorubicin, Cardiomyopathies, Energy Metabolism, Glucose-6-Phosphate. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Doxorubicin (Dox), a potent antitumor drug, is linked to cardiac toxicity. Few mechanism‐based therapies against cardiotoxicity are available. Dysfunction in mitochondrial energy metabolism contributes to Dox‐induced cardiomyopathy. It is aimed at exploring the association between specific mechanism of energy reprogramming and Dox‐induced cardiomyopathy. Cardiac‐specific ablation of Slc25a49 mice are generated by crossing Slc25a49 flox/flox mice with Myh6‐Cre mice. Slc25a49 HKO mice or SLC25A49 KD cardiomyocytes is treated with Dox. Echocardiography, histological analysis, transmission electron microscopy, bulk RNA sequencing, cell bioenergetic profiling, metabolomics test, chromatin immunoprecipitation, and dual‐luciferase reporter assay are conducted to delineate the phenotype and elucidate the molecular mechanisms. Specific ablation of Slc25a49 in cardiomyocytes leads to exacerbated Dox‐induced cardiomyopathy, characterized by compromised mitochondrial respiration enhanced glycolysis and increased glycolytic metabolite glucose‐6‐phosphate (G6P) levels, subsequently activating the activator protein‐1 (AP‐1) complex. The stimulation of the G6P–AP‐1 axis intensifies myocardial damage via transcriptionally regulating Sarcolipin (Sln) expression. Strikingly, targeting of this axis with the AP‐1 inhibitor T‐5224 effectively improves survival and enhances cardiac function in Dox‐induced cardiomyopathy. This study provides mechanistic insights into energy reprogramming that permits myocardial dysfunction, and thus provides a proof of concept for antienergy reprogramming therapy for Dox‐induced cardiomyopathy through directly modulating G6P–AP‐1–Sln axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing, 100193, China.
- Food Science Institute, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310021, China.
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
- Department of General Practice, The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China.
ORCID-Profile: Peng An, Yongting Luo, Junjie Luo
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences
- 2115 Talent Development Program of China Agricultural University, and the Pinduoduo-China Agricultural University Research Fund
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Wan, S., Qi, J., Xia, Y., Fan, C., Xu, T., Zhang, X., Shi, J., Wang, C., Cheng, Y., Zhang, D., Liu, R., Zhu, Y., Cao, C., Jin, D., An, P., Luo, Y., & Luo, J. (2025). Cardiac Slc25a49 ‐Mediated Energy Reprogramming Governs Doxorubicin‐Induced Cardiomyopathy through the G6P–AP‐1–Sln Axis. Advanced Science. https://doi.org/10.1002/advs.202502163
Vancouver
Wan S, Qi J, Xia Y, Fan C, Xu T, Zhang X, et al. Cardiac Slc25a49 ‐Mediated Energy Reprogramming Governs Doxorubicin‐Induced Cardiomyopathy through the G6P–AP‐1–Sln Axis. Advanced Science. 2025. doi:10.1002/advs.202502163
BibTeX
@article{Wan2025,
author = {Wan, Sitong and Qi, Jingyi and Xia, Yi and Fan, Chang and Xu, Teng and Zhang, Xu and Shi, Jiaxin and Wang, Chenxuan and Cheng, Yitong and Zhang, Dongyuan and Liu, Rong and Zhu, Yinhua and Cao, Changchang and Jin, Dekui and An, Peng and Luo, Yongting and Luo, Junjie},
title = {Cardiac Slc25a49 ‐Mediated Energy Reprogramming Governs Doxorubicin‐Induced Cardiomyopathy through the G6P–AP‐1–Sln Axis},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502163}
}
EUVIMED